期刊文献+

非抗心律失常药的致心律失常作用及相关危险因子 被引量:5

Proarrhythmic effects of non-antiarrhythmic agents and related risk factors
下载PDF
导出
摘要 获得性QT间期延长综合征 (LQTS)可由抗心律失常药以外的药物引起 ,包括促胃肠动力药、止吐药、抗心律失常药以外的心血管药物、抗菌药、静脉麻醉药、抗精神病药、抗抑郁药、抗组胺药等 ,它们可阻断心脏的电压门控性通道特别是延迟整流钾电流的快速激活成分 (IKr)、延长动作电位时程(APD)及QT间期、诱发尖端扭转型室性心动过速(TdP)等快速型室性心律失常。一些常见的危险因子如女性 ,电解质紊乱 (特别是低钾、低镁 ) ,临床显著的心动过缓或心脏疾病 ,遗传性LQTS ,肝、肾功能障碍 ,与其他药物合用所致的药动学与药效学的相互作用等通过减少复极储备 。 Acquired long QT syndrome can be induced by non-antiarrhythmic agents. These drugs include gastrointestinal prokinetics, antiemetics, non-antiarrhythmic cardiovascular drugs, antibiotics, intravenous anesthetics, antipsychotics, antidepressants, and antihistamines etc. They share the potential to block cardiac voltage-gated potassium channels, particularly the rapid component (I Kr) of the delayed rectifier potassium current (I K), prolong the QT interval and induce the ventricular tachyarrhythmias like torsades de pointes. Several risk factors can facilitate the proarrhythmic effects of these drugs by reducing the repolarization reserve. These risk factors include female gender, electrolyte imbalance (especially hypokalemia, hypomagnesemia), clinically significant bradycardia or heart disease, congenital long QT syndrome, impaired hepatic/renal function and the pharmacokinetic/pharmacodynamic interactions in the combined treatment with other drugs.
作者 成建华
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2004年第10期713-718,共6页 Chinese Journal of New Drugs and Clinical Remedies
基金 国家教育部留学回国人员启动基金(2 0 10 2 4 10 0 2 )
关键词 钾通道 QT延长综合征 扭转性室速 危险因素 心律失常 potassium channels long QT syndrome torsades de pointes risk factors arrhythmia
  • 相关文献

参考文献40

  • 1[1]de PONTI F, POLUZZI E, MONTANARO N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience[J]. Eur J Clin Pharmacol, 2000, 56(1):1-18.
  • 2[2]de PONTI F, POLUZZI E, MONTANARO N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus[J]. Eur J Clin Pharmacol, 2001, 57(3):185-209.
  • 3[3]HAVERKAMP W, BREITHARDT G, CAMM AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology[J]. Eur Heart J, 2000, 21(15):1216-1231.
  • 4[4]VISWANATHAN PC, SHAW RM, RUDY Y. Effects of IKr and IKs heterogeneity on action potential duration and its rate dependence: a simulation study[J]. Circulation, 1999, 99(18):2466-2474.
  • 5[5]VISWANATHAN PC, RUDY Y. Cellular arrhythmogenic effects of congenital and acquired long-QT syndrome in the heterogeneous myocardium[J]. Circulation, 2000, 101(10):1192-1198.
  • 6[6]RODEN DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes[J]. Pacing Clin Electrophysiol,1998, 21(5):1029-1034.
  • 7[7]TAGLIALATELA M, TIMMERMAN H, ANNUNZIATO L. Cardiotoxic potential and CNS effects of first-generation antihistamines[J]. Trends Pharmacol Sci, 2000, 21(2):52-56.
  • 8[8]KANG J, WANG L, CHEN XL, et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG[J]. Mol Pharmacol, 2001, 59(1): 122-126.
  • 9[9]TAGLIALATELA M, PANNACCIONE A, CASTALDO P, et al. Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines[J]. Mol Pharmacol, 1998, 54(1): 113-121.
  • 10[10]BISCHOFF U, SCHMIDT C, NETZER R, et al. Effects of fluoroquinolones on HERG currents[J]. Eur J Pharmacol, 2000, 406(3): 341-343.

同被引文献106

引证文献5

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部